2023-03-01 2024-02-29 false Capium Accounts Production 1.1 09992952 bus:AbridgedAccounts 2023-03-01 2024-02-29 09992952 bus:FRS102 2023-03-01 2024-02-29 09992952 bus:AuditExemptWithAccountantsReport 2023-03-01 2024-02-29 09992952 bus:SmallCompaniesRegimeForAccounts 2023-03-01 2024-02-29 09992952 bus:PrivateLimitedCompanyLtd 2023-03-01 2024-02-29 09992952 2023-03-01 2024-02-29 09992952 2024-02-29 09992952 bus:RegisteredOffice 2023-03-01 2024-02-29 09992952 core:WithinOneYear 2024-02-29 09992952 core:AfterOneYear 2024-02-29 09992952 bus:Director1 2023-03-01 2024-02-29 09992952 bus:Director1 2024-02-29 09992952 bus:Director1 2022-03-01 2023-02-28 09992952 2022-03-01 09992952 bus:CompanySecretary1 2023-03-01 2024-02-29 09992952 bus:LeadAgentIfApplicable 2023-03-01 2024-02-29 09992952 2022-03-01 2023-02-28 09992952 2023-02-28 09992952 core:WithinOneYear 2023-02-28 09992952 core:AfterOneYear 2023-02-28 09992952 bus:EntityAccountantsOrAuditors 2022-03-01 2023-02-28 09992952 bus:OrdinaryShareClass1 2023-03-01 2024-02-29 09992952 bus:OrdinaryShareClass1 2024-02-29 09992952 bus:OrdinaryShareClass1 2022-03-01 2023-02-28 09992952 bus:OrdinaryShareClass1 2023-02-28 09992952 core:FurnitureFittings 2023-03-01 2024-02-29 09992952 core:FurnitureFittings 2024-02-29 09992952 core:FurnitureFittings 2023-02-28 09992952 core:ComputerEquipment 2023-03-01 2024-02-29 09992952 core:ComputerEquipment 2024-02-29 09992952 core:ComputerEquipment 2023-02-28 09992952 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-02-29 09992952 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2023-02-28 09992952 core:CostValuation core:Non-currentFinancialInstruments 2024-02-29 09992952 core:CostValuation core:Non-currentFinancialInstruments 2023-02-28 09992952 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-02-29 09992952 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-02-29 09992952 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-02-29 09992952 core:Non-currentFinancialInstruments 2024-02-29 09992952 core:Non-currentFinancialInstruments 2023-02-28 09992952 core:ShareCapital 2024-02-29 09992952 core:ShareCapital 2023-02-28 09992952 core:RetainedEarningsAccumulatedLosses 2024-02-29 09992952 core:RetainedEarningsAccumulatedLosses 2023-02-28 09992952 dpl:Item1 2023-03-01 09992952 dpl:Item1 2024-02-29 09992952 dpl:Item1 2022-03-01 09992952 dpl:Item1 2023-02-28 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 09992952
England and Wales

 

 

 


Abridged Accounts

for the year ended 29 February 2024

for

UROLOGICAL CANCER SERVICES LTD

Chartered Accountant's report to the board of directors on the preparation of the unaudited statutory financial statements of Urological Cancer Services Ltd for the year ended 29 February 2024.


In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Urological Cancer Services Ltd for the year ended 29 February 2024 which comprise the Statement of Comprehensive Income, the Statement of Financial Position, the Statement of Changes in Equity, the Statement of Cash Flows and related notes from the companys accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales, we are subject to its ethical and other professional requirements which are detailed at http://icaew.com/regulations.

This report is made solely to the Board of Directors of Urological Cancer Services Ltd, as a body, in accordance with the terms of our engagement letter dated 11th February 2016. Our work has been undertaken solely to prepare for your approval the financial statements of Urological Cancer Services Ltd and state those matters that we have agreed to state to the Board of Directors of Urological Cancer Services Ltd, as a body, in this report in accordance with AAF 2/10 as detailed at http://icaew.com/compilation. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Urological Cancer Services Ltd and its Board of Directors as a body, for our work or for this report.

It is your duty to ensure that Urological Cancer Services Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Urological Cancer Services Ltd. You consider that Urological Cancer Services Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Urological Cancer Services Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.



....................................................
KWSR & CO LTD
136 Merton High Street
London
SW19 1BA
26 March 2024
1
 
 
Notes
 
2024
£
  2023
£
Fixed assets      
Tangible fixed assets 3 1,202    1,414 
1,202    1,414 
Current assets      
Cash at bank and in hand 90,703    35,628 
Creditors: amount falling due within one year (21,258)   (12,552)
Net current assets 69,445    23,076 
 
Total assets less current liabilities 70,647    24,490 
Net assets 70,647    24,490 
 

Capital and reserves
     
Called up share capital 4 100    100 
Profit and loss account 70,547    24,390 
Shareholder's funds 70,647    24,490 
 


For the year ended 29 February 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).
The financial statements were approved by the director on 26 March 2024 and were signed by:


-------------------------------
Alan Thompson
Director
2
General Information
Urological Cancer Services Ltd is a private company, limited by shares, registered in England and Wales, registration number 09992952, registration address 12 Copsem Drive, Esher, Surrey, KT10 9HD.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by Section 1A of the standard) and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Website cost
Planning and operating costs for the company's website are charged to the income statement as incurred.
Taxation
Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Current and deferred tax assets and liabilities are not discounted
Dividends
Proposed dividends are only included as liabilities in the statement of financial position when their payment has been approved by the shareholders prior to the statement of financial position date.
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Fixtures and Fittings 15% Reducing Balance
Computer Equipment 15% Reducing Balance
2.

Average number of employees

Average number of employees during the year was 0 (2023 : 0).
3.

Tangible fixed assets

Cost or valuation Fixtures and Fittings   Computer Equipment   Total
  £   £   £
At 01 March 2023 1,600    1,799    3,399 
Additions    
Disposals    
At 29 February 2024 1,600    1,799    3,399 
Depreciation
At 01 March 2023 932    1,053    1,985 
Charge for year 100    112    212 
On disposals    
At 29 February 2024 1,032    1,165    2,197 
Net book values
Closing balance as at 29 February 2024 568    634    1,202 
Opening balance as at 01 March 2023 668    746    1,414 


4.

Share Capital

Allotted, called up and fully paid
2024
£
  2023
£
100 Ordinary shares of £1.00 each 100    100 
100    100 

3